Related Experiment Videos
Antibody studies of factor VIII inhibitor in a case with Waldenström's macroglobulinemia
1Department of Clinical Laboratory, Yamanashi Medical University Hospital, Yamanashi, Japan.
American Journal of Hematology
|February 19, 2000
Abstract:
We report a case of Waldenström's macroglobulinemia with prominent bleeding tendency; laboratory investigation revealed an elevated activated partial thromboplastin time. Further laboratory evaluation showed circulating factor VIII anticoagulant, deemed polyclonal IgG, with a titer of 700 Bethesda Units/ml. The factor VIII inactivation kinetics of the patient plasma were identical to those of a type II inhibitor, and the inhibitor was found to recognize the A2 domain of the factor VIII heavy chain. Apparently, paraprotein is not always the cause of reduced activity of coagulation factors in neoplastic dysproteinemias.